The active metabolite of the prodrug Trandolapril.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Aliskiren | The risk or severity of hypotension, hyperkalemia, and nephrotoxicity can be increased when Aliskiren is combined with Trandolaprilat. |
| Allopurinol | The risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Trandolaprilat. |
| Aprotinin | Aprotinin may decrease the antihypertensive activities of Trandolaprilat. |
| Azathioprine | The risk or severity of myelosuppression, anemia, and severe leukopenia can be increased when Trandolaprilat is combined with Azathioprine. |
| Dapagliflozin | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Dapagliflozin is combined with Trandolaprilat. |
| Canagliflozin | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Trandolaprilat. |
| Ertugliflozin | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Ertugliflozin is combined with Trandolaprilat. |
| Empagliflozin | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Trandolaprilat. |
| Dapoxetine | Dapoxetine may increase the orthostatic hypotensive activities of Trandolaprilat. |
| Drospirenone | Trandolaprilat may increase the hyperkalemic activities of Drospirenone. |
| Eplerenone | Eplerenone may increase the hyperkalemic activities of Trandolaprilat. |
| Everolimus | The risk or severity of adverse effects can be increased when Everolimus is combined with Trandolaprilat. |
| Sirolimus | The risk or severity of adverse effects can be increased when Sirolimus is combined with Trandolaprilat. |
| Ardeparin | The risk or severity of hyperkalemia can be increased when Trandolaprilat is combined with Ardeparin. |
| Heparin | The risk or severity of hyperkalemia can be increased when Trandolaprilat is combined with Heparin. |
| Enoxaparin | The risk or severity of hyperkalemia can be increased when Trandolaprilat is combined with Enoxaparin. |
| Sulodexide | The risk or severity of hyperkalemia can be increased when Trandolaprilat is combined with Sulodexide. |
| Semuloparin | The risk or severity of hyperkalemia can be increased when Trandolaprilat is combined with Semuloparin. |
| Danaparoid | The risk or severity of hyperkalemia can be increased when Trandolaprilat is combined with Danaparoid. |
| Dalteparin | The risk or severity of hyperkalemia can be increased when Trandolaprilat is combined with Dalteparin. |
| Tinzaparin | The risk or severity of hyperkalemia can be increased when Trandolaprilat is combined with Tinzaparin. |
| Nadroparin | The risk or severity of hyperkalemia can be increased when Trandolaprilat is combined with Nadroparin. |
| Bemiparin | The risk or severity of hyperkalemia can be increased when Trandolaprilat is combined with Bemiparin. |
| Parnaparin | The risk or severity of hyperkalemia can be increased when Trandolaprilat is combined with Parnaparin. |
| Reviparin | The risk or severity of hyperkalemia can be increased when Trandolaprilat is combined with Reviparin. |
| Icatibant | Icatibant may decrease the antihypertensive activities of Trandolaprilat. |
| Lithium citrate | The serum concentration of Lithium citrate can be increased when it is combined with Trandolaprilat. |
| Lithium carbonate | The serum concentration of Lithium carbonate can be increased when it is combined with Trandolaprilat. |
| Lithium hydroxide | The serum concentration of Lithium hydroxide can be increased when it is combined with Trandolaprilat. |
| Tizanidine | The risk or severity of hypotension can be increased when Tizanidine is combined with Trandolaprilat. |
| Tolvaptan | Tolvaptan may increase the hyperkalemic activities of Trandolaprilat. |
| Trimethoprim | Trimethoprim may increase the hyperkalemic activities of Trandolaprilat. |
| Sodium aurothiomalate | The risk or severity of hypotension, nitritoid reactions, facial flushing, nausea, and vomiting can be increased when Trandolaprilat is combined with Sodium aurothiomalate. |
| Nicorandil | Nicorandil may increase the vasodilatory activities of Trandolaprilat. |
| Sacubitril | The risk or severity of angioedema can be increased when Trandolaprilat is combined with Sacubitril. |
| Ciprofloxacin | The risk or severity of hyperkalemia can be increased when Trandolaprilat is combined with Ciprofloxacin. |
| Iron | The risk or severity of adverse effects can be decreased when Iron is combined with Trandolaprilat. |
| Icosapent | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Icosapent is combined with Trandolaprilat. |
| Mesalazine | The risk or severity of renal failure can be increased when Mesalazine is combined with Trandolaprilat. |
| Indomethacin | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indomethacin is combined with Trandolaprilat. |
| Nabumetone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nabumetone is combined with Trandolaprilat. |
| Ketorolac | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ketorolac is combined with Trandolaprilat. |
| Tenoxicam | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tenoxicam is combined with Trandolaprilat. |
| Celecoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Celecoxib is combined with Trandolaprilat. |
| Tolmetin | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolmetin is combined with Trandolaprilat. |
| Rofecoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Rofecoxib is combined with Trandolaprilat. |
| Piroxicam | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Piroxicam is combined with Trandolaprilat. |
| Fenoprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fenoprofen is combined with Trandolaprilat. |
| Valdecoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Valdecoxib is combined with Trandolaprilat. |
| Diclofenac | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Diclofenac is combined with Trandolaprilat. |
| Sulindac | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Trandolaprilat. |
| Flurbiprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Flurbiprofen is combined with Trandolaprilat. |
| Etodolac | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Etodolac is combined with Trandolaprilat. |
| Mefenamic acid | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mefenamic acid is combined with Trandolaprilat. |
| Naproxen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Trandolaprilat. |
| Sulfasalazine | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Trandolaprilat. |
| Phenylbutazone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Phenylbutazone is combined with Trandolaprilat. |
| Carprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Carprofen is combined with Trandolaprilat. |
| Diflunisal | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Diflunisal is combined with Trandolaprilat. |
| Salicylic acid | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Salicylic acid is combined with Trandolaprilat. |
| Meclofenamic acid | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Meclofenamic acid is combined with Trandolaprilat. |
| Oxaprozin | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Oxaprozin is combined with Trandolaprilat. |
| Ketoprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ketoprofen is combined with Trandolaprilat. |
| Balsalazide | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Balsalazide is combined with Trandolaprilat. |
| Ibuprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Trandolaprilat. |
| Olsalazine | The risk or severity of renal failure can be increased when Olsalazine is combined with Trandolaprilat. |
| Lumiracoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Lumiracoxib is combined with Trandolaprilat. |
| Magnesium salicylate | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Magnesium salicylate is combined with Trandolaprilat. |
| Salsalate | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Salsalate is combined with Trandolaprilat. |
| Choline magnesium trisalicylate | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Choline magnesium trisalicylate is combined with Trandolaprilat. |
| Antrafenine | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Antrafenine is combined with Trandolaprilat. |
| Aminophenazone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Aminophenazone is combined with Trandolaprilat. |
| Antipyrine | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Antipyrine is combined with Trandolaprilat. |
| Tiaprofenic acid | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tiaprofenic acid is combined with Trandolaprilat. |
| Etoricoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Etoricoxib is combined with Trandolaprilat. |
| Taxifolin | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Taxifolin is combined with Trandolaprilat. |
| Oxyphenbutazone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Oxyphenbutazone is combined with Trandolaprilat. |
| Licofelone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Licofelone is combined with Trandolaprilat. |
| Nimesulide | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Trandolaprilat. |
| Benoxaprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Benoxaprofen is combined with Trandolaprilat. |
| Zomepirac | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Zomepirac is combined with Trandolaprilat. |
| Cimicoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Cimicoxib is combined with Trandolaprilat. |
| Lornoxicam | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Lornoxicam is combined with Trandolaprilat. |
| Aceclofenac | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Aceclofenac is combined with Trandolaprilat. |
| Zaltoprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Zaltoprofen is combined with Trandolaprilat. |
| Azapropazone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Azapropazone is combined with Trandolaprilat. |
| Parecoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Parecoxib is combined with Trandolaprilat. |
| Salicylamide | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Salicylamide is combined with Trandolaprilat. |
| Kebuzone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Kebuzone is combined with Trandolaprilat. |
| Isoxicam | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Isoxicam is combined with Trandolaprilat. |
| Indoprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indoprofen is combined with Trandolaprilat. |
| Ibuproxam | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuproxam is combined with Trandolaprilat. |
| Floctafenine | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Floctafenine is combined with Trandolaprilat. |
| Fenbufen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fenbufen is combined with Trandolaprilat. |
| Etofenamate | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Etofenamate is combined with Trandolaprilat. |
| Epirizole | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Epirizole is combined with Trandolaprilat. |
| Benzydamine | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Benzydamine is combined with Trandolaprilat. |
| Dexibuprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Dexibuprofen is combined with Trandolaprilat. |
| Dexketoprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Dexketoprofen is combined with Trandolaprilat. |
| Droxicam | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Droxicam is combined with Trandolaprilat. |